Mobile

A Randomized, double blind study to determine the effect of two dose schedules of R1507 or placebo, both in combination with erlotinib (Tarceva®), on progression-free survival in patients with advance...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-001736-12

A Randomized, double blind study to determine the effect of two dose schedules of R1507 or placebo, both in combination with erlotinib (Tarceva®), on progression-free survival in patients with advanced non-small cell lung cancer with disease progression after first or second line chemotherapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To define the proportion of patients with PFS at 12 weeks with the combination of R1507 and erlotinib or a corresponding placebo and erlotinib in patients with advanced Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) who have failed at least one standard chemotherapy regimen.

Critère d'inclusion

  • Advanced (Stage IIIb/IV) Non Small Cell Lung Cancer patients who have failed at least one but no more than two standard chemotherapy regimens

Liens